Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA and TKI in Chronic Myeloid Leukemia
NCT04006847Phase 2Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid in chronic myeloid leukemia (CML), sponsored by Penn State Health Milton S. Hershey Medical Center. Started Sep 2020; status: terminated.
02
Drugs
eicosapentaenoic acid
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04006847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006847.